Application of VGF as diagnostic biomarker for prostate cancer
By detecting VGF expression in prostatic fluid, the problems of invasiveness and false positives in prostate cancer diagnosis have been solved, providing a non-invasive and convenient diagnostic method, improving diagnostic accuracy and specificity, and filling the gaps in existing biomarkers.
Patent Information
- Application Number
- CN202511954047.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-23
- Publication Date
- 2026-03-20
AI Technical Summary
The lack of highly specific prostate cancer tumor markers in existing technologies leads to invasiveness and false negative results in biopsy. Furthermore, the positive rate of prostate biopsy in my country is less than 50%, indicating a serious problem of over-invasive diagnosis.
Using VGF as a diagnostic biomarker for prostate cancer, non-invasive early screening and prognostic assessment can be provided by detecting VGF expression levels in prostatic fluid, combined with existing procedures such as PSA and mpMRI, avoiding repeated biopsies.
It enables non-invasive and convenient diagnosis of prostate cancer, improves the accuracy and specificity of diagnosis, reduces the false positive rate, is compatible with existing diagnostic procedures, is low in cost, and has good diagnostic efficacy (AUC value of 0.751).